MFN — once a policy abstraction — is now reshaping corporate strategy, pricing frameworks, and commercialization models.

The newest pharmaceutical behemoths to reach MFN pricing agreements with the White House are Eli Lilly and Novo Nordisk, who have agreed to sell their weight-loss medications to Americans at reduced costs.